Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept-Reference-Cited by-同舟云学术

Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept

Published:2018-02-09 Issue:3 Volume:11 Page:361-369
ISSN:1178-1653
Container-title:The Patient - Patient-Centered Outcomes Research
language:en
Short-container-title:Patient

Author:

Dehoratius Raphael J.,Brent Lawrence H.,Curtis Jeffrey R.,Ellis Lorie A,Tang Kezhen L.

Funder

Janssen Research and Development

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/article/10.1007/s40271-018-0297-5/fulltext.html

Reference14 articles.

1. Crow R, Gage H, Hampson S, et al. The measurement of satisfaction with healthcare: implications for practice from a systematic review of the literature. Health Technol Assess. 2002;6:1–244.

2. Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med. 2008;31:213–24.

3. Barton JL. Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy. Patient Prefer Adherence. 2009;3:335–44.

4. Poulos C, Hauber AB, González JM, et al. Patients’ willingness to trade off between the duration and frequency of rheumatoid arthritis treatments. Arthritis Care Res (Hoboken). 2014;66:1008–15.

5. Bolge SC, Goren A, Tandon N. Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective. Patient Prefer Adherence. 2015;9:121–31.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient self-reported experience and satisfaction with golimumab and etanercept treatments for rheumatic diseases: A cohort study;Medicine;2024-02-23

2. Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients;Indian Journal of Gastroenterology;2024-01-20

3. The etiology, pathogenesis, treatment, and development of transdermal drug delivery systems for rheumatoid arthritis;RSC Pharmaceutics;2024

4. Safety and Efficacy of Golimumab in Rheumatoid Arthritis: A Prospective, Multicenter, Real-World Study from India;Indian Journal of Rheumatology;2023-07-14

5. Real‐world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease;Alimentary Pharmacology & Therapeutics;2022-04-25